Future AML Therapy
Future Treatment Strategies for Acute Myeloid Leukemia—Emerging Targeted Therapy Combinations and Beyond

Released: August 14, 2020

Expiration: August 13, 2021

Naval G. Daver
Naval G. Daver, MD

Activity

Progress
1
Course Completed

In this episode, Naval G. Daver, MD, discusses promising investigational agents and treatment combinations in clinical trials for patients with newly diagnosed and relapsed/refractory AML, including:

  • FLT3 inhibitors crenolanib and quizartinib
  • Anti-CD47 antibody magrolimab
  • IMGN632, a CD123 antibody–drug conjugate
  • Anti-CD70 antibody cusatuzumab
  • APR-246, targeting the TP53 mutation

Content is part of an online CME program supported by an educational grant from Daiichi-Sankyo.

Link to full program, including a ClinicalThought commentary: https://www.clinicaloptions.com/oncology/programs/aml-2020